Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2014

View Archived Issues

Biomarkers may identify patients with dengue with warning signs

Phase II results indicate cutamesine may be more effective in moderate-to-severe stroke

Pim kinase inhibitor found to sensitize SCLC cells to BH3 mimetic

Recombinant NDV-GM-CSF: a lead project from MedImmune's NDV oncolytic platform

Synthon initiates first-in-human study of HER2-targeted ADC SYD-985

Isis Pharmaceuticals earns milestone payment for advancing ISIS-BIIB3Rx

Oral JAK1 inhibitor shows dose-dependent activity in phase II psoriasis trial

Arcturus Therapeutics expands operations to support RNA drug discovery

Omeros reports data for OMS-721 derivative in experimental model of stroke

Leading BioSciences submits IND for drug to treat Ebola-related shock, multiorgan failure

New biomarkers to improve sensitivity and specificity of diagnosing endometriosis

Cantrixil shows activity in animal model of paclitaxel-resistant ovarian cancer

Deutetrabenazine classified as orphan drug by the FDA

AstraZeneca reviews highlights of third quarter 2014

Sage Therapeutics discloses new GABA(A) receptor modulators

Pfizer patents novel PCSK9 inhibitors

Merck & Co. patent reports new HIV integrase inhibitors

New methyltransferase inhibitors designed by U.S. researchers

Lundbeck and Vernalis disclose novel LRRK2 inhibitors

IRCM to create spin-off company Liphorus Pharmaceuticals

Janssen Pharmaceutica patents novel NIK inhibitors for cancer

Perrigo to acquire Omega Pharma

Johnson & Johnson completes acquisition of Alios BioPharma

FDA committee votes against recommending approval of panobinostat

Phase I/II data for HepaStem in urea cycle disorders and Crigler-Najjar syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...